MedTrace Logo

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region

NCT01800006 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2101

Last updated 2017-06-21

No results posted yet for this study

Summary

This international study is a prospective noninterventional observational cohort study of patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Patients will be followed up for 1 year or until 30 days after end of rivaroxaban therapy in case of therapy was discontinued earlier than 12 months. Serious adverse events will be followed up adequately. Laboratory values (e.g., Hb, HCT, haemoccult) should be documented for each point in time they were measured.

Conditions

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-14
Primary Completion
2016-01-16
Completion
2016-06-20

Countries

  • Argentina
  • Azerbaijan
  • Bahrain
  • Chile
  • Colombia
  • Egypt
  • Georgia
  • Jordan
  • Kazakhstan
  • Kenya
  • Lebanon
  • Mexico
  • Russia
  • Saudi Arabia
  • United Arab Emirates
  • Uruguay
  • Venezuela

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01800006 on ClinicalTrials.gov